Statins-mediated inhibition of Rho GTPases as a potential tool in anti-tumor therapy
Mini-Reviews in Medicinal Chemistry, ISSN: 1389-5575, Vol: 8, Issue: 6, Page: 609-618
2008
- 18Citations
- 14Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations18
- Citation Indexes18
- 18
- CrossRef7
- Captures14
- Readers14
- 14
Review Description
Rho GTPases, which control processes such as cell proliferation and cytoskelelon remodeling, are often hyper-expressed in tumors. Several members, such as RhoA/B/C, must be isoprenylated to interact with their effectors. Statins, by inhibiting the synthesis of prenyl groups, may affect RhoA/B/C activity and represent a promising tool in anticancer therapy. © 2008 Bentham Science Publishers Ltd.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=49649089730&origin=inward; http://dx.doi.org/10.2174/138955708784534436; http://www.ncbi.nlm.nih.gov/pubmed/18537716; http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-5575&volume=8&issue=6&spage=609; https://dx.doi.org/10.2174/138955708784534436; https://www.eurekaselect.com/article/27723
Bentham Science Publishers Ltd.
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know